124 related articles for article (PubMed ID: 35922259)
1. Comparative study on the antitumor effects of gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human MUC1 and CA199 monoclonal antibodies on pancreatic cancer in vitro and in vivo.
Zhang L; Hou Y; Li C; Liu H; Wang Y
Arab J Gastroenterol; 2022 Nov; 23(4):263-269. PubMed ID: 35922259
[TBL] [Abstract][Full Text] [Related]
2. A study on the antitumor effect of gemcitabine polybutylcy- anoacrylate nanoparticles coupled with Mucin 1 monoclonal antibody on pancreatic cancer
Zhang L; Zhu J; Hou Y; Li C; Liu H
J Cancer Res Ther; 2021 Dec; 17(7):1702-1708. PubMed ID: 35381742
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
Zhang ZM; Yang XY; Deng SH; Xu W; Gao HQ
Chin Med J (Engl); 2007 Aug; 120(15):1336-42. PubMed ID: 17711740
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-tumor effects of doxorubicin on glioma by entrapping in polybutylcyanoacrylate nanoparticles.
Zhang Y; Yu J; Zhang L; Cai J; Cai D; Lv C
Tumour Biol; 2016 Feb; 37(2):2703-8. PubMed ID: 26404136
[TBL] [Abstract][Full Text] [Related]
5. [Effect of diameter of adriamycin polybutylcyanoacrylate nanoparticles on liver targeting].
Shen LF; Wang X; Wang C; Zhao K; Liu XJ; Shen HJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):732-6, 741. PubMed ID: 17062941
[TBL] [Abstract][Full Text] [Related]
6. Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy.
Behl A; Sarwalia P; Kumar S; Behera C; Mintoo MJ; Datta TK; Gupta PN; Chhillar AK
Mol Pharm; 2022 Jul; 19(7):2429-2440. PubMed ID: 35639628
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
8. Liver targeting and the delayed drug release of the nanoparticles of adriamycin polybutylcyanoacrylate in mice.
Shen LF; Zhang YD; Shen HJ; Zeng S; Wang X; Wang C; Le Y; Shen H
Chin Med J (Engl); 2006 Aug; 119(15):1287-93. PubMed ID: 16919188
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model.
Wang CX; Huang LS; Hou LB; Jiang L; Yan ZT; Wang YL; Chen ZL
Brain Res; 2009 Mar; 1261():91-9. PubMed ID: 19401168
[TBL] [Abstract][Full Text] [Related]
10. [Study of biocompatibility of polybutylcyanoacrylate nanoparticles].
Yang XX; Chen JH; Guo D
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1261-3. PubMed ID: 16234103
[TBL] [Abstract][Full Text] [Related]
11. In vivo anti-MUC1
Pichinuk E; Chalik M; Benhar I; Ginat-Koton R; Ziv R; Smorodinsky NI; Haran G; Garbar C; Bensussan A; Meeker A; Guillaume T; Rubinstein DB; Wreschner DH
Cancer Immunol Immunother; 2020 Jul; 69(7):1337-1352. PubMed ID: 32219500
[TBL] [Abstract][Full Text] [Related]
12. A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model.
Wu G; Maharjan S; Kim D; Kim JN; Park BK; Koh H; Moon K; Lee Y; Kwon HJ
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987260
[TBL] [Abstract][Full Text] [Related]
13. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
[TBL] [Abstract][Full Text] [Related]
14. MUC-1 aptamer targeted superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of pancreatic cancer in vivo and in vitro experiment.
Zou Q; Zhang CJ; Yan YZ; Min ZJ; Li CS
J Cell Biochem; 2019 Nov; 120(11):18650-18658. PubMed ID: 31338877
[TBL] [Abstract][Full Text] [Related]
15. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.
Olivier JC; Fenart L; Chauvet R; Pariat C; Cecchelli R; Couet W
Pharm Res; 1999 Dec; 16(12):1836-42. PubMed ID: 10644071
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
Li Y; Chen Y; Li J; Zhang Z; Huang C; Lian G; Yang K; Chen S; Lin Y; Wang L; Huang K; Zeng L
Cancer Sci; 2017 Jul; 108(7):1493-1503. PubMed ID: 28444967
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
Shindo Y; Hazama S; Maeda Y; Matsui H; Iida M; Suzuki N; Yoshimura K; Ueno T; Yoshino S; Sakai K; Suehiro Y; Yamasaki T; Hinoda Y; Oka M
J Transl Med; 2014 Jun; 12():175. PubMed ID: 24947606
[TBL] [Abstract][Full Text] [Related]
18. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
RĂ©jiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
19. Polybutylcyanoacrylate nanoparticles as a carrier for mitomycin C in rabbits bearing VX2-liver tumor.
Xi-Xiao Y; Jan-Hai C; Shi-Ting L; Dan G; Xv-Xin Z
Regul Toxicol Pharmacol; 2006 Dec; 46(3):211-7. PubMed ID: 17010489
[TBL] [Abstract][Full Text] [Related]
20. Visualization research on ENT1/NIS dual-function gene therapy to reverse drug resistance mediated by MUC1 in GEM-resistant pancreatic cancer.
Xi Y; Chen H; Xi Y; Hai W; Qu Q; Zhang M; Li B
Nucl Med Biol; 2023; 120-121():108350. PubMed ID: 37229950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
